Clinical Trial Update: QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

View source ↗

Summary

Clinical trial update for QL706 in combination with chemotherapy with or without bevacizumab in anti-PD-(L)1-resistant recurrent/metastatic cervical cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• QL706

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Recurrent Cervical Cancer, Metastatic Cervical Cancer | Status: NOT_YET_RECRUITING